Blog
RSS FeedPosted by Michael Wonder on 14 Dec 2018
Decision in relation to infliximab, tocilizumab and rituximab
14 December 2018 - PHARMAC is pleased to announce a decision on how three hospital medicines (infliximab, tocilizumab and rituximab) ...
Posted by Michael Wonder on 13 Dec 2018
Frustrated at cancer treatment inequity
13 December 2018 - As appointed ambassador for the Lung Foundation NZ, I feel very frustrated the Government will not ...
Posted by Michael Wonder on 12 Dec 2018
Health organisations join calls for a review into government drug buying agency
12 December 2018 - Pressure is mounting on the government to announce a review into its drug buying agency with ...
Posted by Michael Wonder on 11 Dec 2018
Decision to list a new brand of iron polymaltose (Ferrosig)
11 December 2018 - PHARMAC is pleased to announce a decision to list a new brand of iron polymaltose inj ...
Posted by Michael Wonder on 10 Dec 2018
Breast cancer sufferer fighting for life-extending drugs wants PHARMAC inquiry
10 December 2018 - A woman fighting stage 4 breast cancer is a "little shy" of the $77,000 she needs ...
Posted by Michael Wonder on 10 Dec 2018
Proposal to open access to atomoxetine and change funded brand
10 December 2018 - PHARMAC is proposing to remove all funding restrictions from all presentations of atomoxetine, and change the ...
Posted by Michael Wonder on 07 Dec 2018
Proposal to list a new presentation of raltegravir and amend arrangements for raltegravir and posaconazole
7 December 2018 - PHARMAC is seeking feedback on a multi-product proposal with Merck Sharpe & Dohme. ...
Posted by Michael Wonder on 06 Dec 2018
Trapped abroad: NZ a 'death sentence' if she comes home
6 December 2018 - Rachel Paine never meant to settle overseas but coming home risks death. ...
Posted by Michael Wonder on 05 Dec 2018
PHARMAC - 2018 in review (update)
6 December 2018 - Further analysis of the ten new patent protected medicines (i.e. new chemical entities) listed in the ...
Posted by Michael Wonder on 04 Dec 2018
Mulholland supports calls for PHARMAC Inquiry
4 December 2018 - Stage four breast cancer sufferer Wiki Mulholland is supporting calls for an Inquiry into PHARMAC. ...
Posted by Michael Wonder on 03 Dec 2018
PHARMAC - 2018 in review
4 December 2018 - Yet another disappointing year in terms of patients in New Zealand being able to obtain subsidised ...
Posted by Michael Wonder on 30 Nov 2018
New Zealand Pharmaceutical Schedule - 1 December 2018 update
1 December 2018 - The December 2018 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Nov 2018
Proposal involving treatments for multiple sclerosis, narcolepsy and attention deficit hyperactivity disorder
30 November 2018 - PHARMAC is seeking feedback on a proposal involving the following products through a provisional agreement with ...
Posted by Michael Wonder on 30 Nov 2018
Decision to fund ceftriaxone in the community for suspected meningococcal disease
30 November 2018 - PHARMAC has widened funded access to ceftriaxone to enable its use for the treatment of suspected ...
Posted by Michael Wonder on 21 Nov 2018
National paracetamol shortage leads to restrictions
21 November 2018 - Pharmacists have been told to restrict the number of paracetamol tablets they give out because of a ...